Diffuse Midline Glioma H3 K27M-Mutant

Symptoms, Doctors, Treatments, Advances & More

Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Pediatric Low-Grade Glioma (pLGG). Dr. Raabe is board certified in American Board Of Pediatrics.

Dr. Koschmann is a Pediatric Neuro-Oncologist in the Department of Pediatrics and a Principal Investigator of an independent translational Pediatric Neuro-Oncology laboratory. His work in the clinic and lab complement and drive each other, resulting in a clear goal to improve therapies for children with brain tumors. He has engaged in research and the clinical care of pediatric brain tumor patients at both Seattle Children’s Hospital and the University of Michigan’s Mott Children’s Hospital. The Koschmann laboratory is exploring the molecular mechanisms by which recurrent mutations in pediatric high-grade glioma (HGG), including glioblastoma (GBM), anaplastic astrocytoma (AA) and diffuse intrinsic pontine glioma (DIPG) promotes tumor formation and affect treatment response.Dr. Koschmann has applied this precision medicine approach in translational and clinical work in Pediatric Neuro-Oncology. Along with researchers and colleagues from multiple clinical divisions at the University of Michigan and other institutions, he developed and co-facilitate the UM CNS Precision Medicine conference. In this multi-disciplinary and multi-institutional conference, molecular results are incorporated from pediatric brain tumor patients (paired tumor/germline sequencing results and pre-clinical cell culture treatment studies) into their treatment. Dr. Koschmann has established new algorithms and are in the process of developing multiple clinical trials incorporating the use of molecularly targeted therapy for pediatric patients with brain tumors. He will serve as PI for these trials and their biologic correlative research. Dr. Koschmann is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Glioma, Brain Stem Cancer, and Embryonal Tumor with Multilayered Rosettes. Dr. Koschmann is board certified in Pediatric Hematology-Oncology and Pediatrics.

Alberto Broniscer is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Broniscer is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Medulloblastoma.